Overactive bladder treatments in early phase clinical trials

Expert Opinion on Investigational Drugs

Volumn 16, Issue 7, 2007, Pages 999-1007

  Colli, Enrico ^a   Digesu, Giuseppe Alessandro ^b   Olivieri, Lorenza ^a  

^a BioXell SpA   (Italy)

^b V BUZZI CHILDREN S HOSPITAL   (Italy)

Author keywords

A 278637; KW 7158; NS 8; Overactive bladder; ZD 6169

Indexed keywords

A 251179; A 278637; APREPITANT; BESIPIRDINE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BXL 628; COLECALCIFEROL DERIVATIVE; DIHYDROPYRIDINE DERIVATIVE; ELOCALCITOL; FLURBIPROFEN 4 NITROXYBUTYL ESTER; KIL 769; KUC 7483; KW 7158; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NS 309; NS 8; OXYBUTYNIN; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; REC 0545; SEROTONIN 1A ANTAGONIST; SOLABEGRON; SSR 240600; SULFONYLDIHYDROPYRIDINE DERIVATIVE; TA 5538; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 178; ZD 0947;

CLINICAL TRIAL; DETRUSOR MUSCLE; DRUG ABSORPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SYNTHESIS; HUMAN; MICTURITION; NONHUMAN; OVERACTIVE BLADDER; PATIENT COMPLIANCE; REVIEW; STRUCTURE ACTIVITY RELATION; URINARY FREQUENCY;

ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DISEASE MODELS, ANIMAL; DRUGS, INVESTIGATIONAL; GUANIDINES; HUMANS; MICE; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; RECEPTORS, MUSCARINIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TETRAHYDROISOQUINOLINES; URINARY BLADDER, OVERACTIVE;

EID: 34447542939     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.7.999     Document Type: Review

References (40)

1. EDWARDS G, HENSHAW M, MILLER M, WESTON AH: Comparison of the effects of several potassium-channel openers on rat bladder and rat portal vein in vitro. Br. J. Pbarmacol. (1991) 102:679-686.
2. BARRAS M, VAN DER GRAF PH, CHRISTOPH P, ITZCHAK A. Relaxant efficacy of potassium channel openers in rabbit isolated bladder and mesenteric artery. Eur. J. Urol. (1996) 30(Suppl. 2):240.
3. HEDLUND H, ANDERSSON K-E, MATTIASSON A: Effects of pinacidil on detrusor instability in men with outlet obstruction. J. Urol. (1991) 146:1345-1347.
4. KOMERSOVA K, ROGERSON JW, CONWAY EL et al.: The effect of levcromakalim (BRL 38227) on bladder function in patients with high spinal cord lesions. Br. J. Pharmacol. (1995) 39:207-209.
5. MAZZUCCO R: American Urological Association - 96th Annual Meeting. 2-7 June 2001, Anaheim, CA, USA. IDrugs (2001) 4(8):892-895.
6. CONTRAFOURIS Y: Medicinal Chemistry - XVIIth International Symposium. IDrugs (2002) 5(10):961-963.
7. PEREZ-MEDRANO A, KORT ME, GREGG RJ et al.: Buckner design and synthesis of aminal-containing ATP-sensitive potassium channel openers for the treatment of bladder overactivity. 224th American Chemical Society Meeting, Boston, USA (18 - 22 August 2002).
8. JAEHNE G, LANG HJ, GLOMBIK H, GEISEN K et al.: In vivo anorectic activity of substituted tetrahydro-indeno[1,2-d]thiazols. 224th American Chemical Society Meeting, Boston, MA, USA (18 - 22 August 2002).
9. + channel opener targeted for overactive bladder: synthesis and structure-activity relationships of 2-amino-4-azaindoles. Bioorg. Med. Chem. Lett. (2003) 13(12):2003-2007.
10. ATP opener that selectively inhibits spontaneous bladder contractions. J. Med. Chem. (2004) 47(12):3163-3179.
11. PEREZ-MEDRANO A, BUCKNER SA, COGHLAN MJ et al.: Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder. Bioorg. Med. Chem. Lett. (2004) 14(2):397-400.
12. PEREZ-MEDRANO A, BUCKNER SA, COGHLAN MJ et al.: Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder. Bioorg. Med. Chem. Lett. (2004) 14(2):397-400.
13. + channel opener targeted for overactive bladder: synthesis and structure-activity relationships of 2-amino-4-azaindoles. Bioorg. Med. Chem. Lett. (2003) 13(12):2003-2007.
14. + channels. Society of Neuroscience Abstracts (2003):33.
15. WICKENDEN A: SRI's Second International Symposium on Ion Channels in Drug Discovery and Development, Princeton, NJ, USA, 24 - 25 October (2002).
16. HEWAWASAM P, ERWAY M, THALODY G et al. The synthesis and structure-activity relationships of 1,3-diaryl 1,2,4(4H)-triazol-5-ones: a new class of calcium-dependent, large conductance, potassium (Maxi-K) channel opener targeted for urge urinary incontinence. Bioorg. Med. Chem. Lett. (2002) 12(7):1117-1120.
17. + channel openers, KRN2391 and Ki1769, and nitroglycerine on the urinary tract of rats in vivo. Jpn. J. Pharmacol. (1999) 80(2):143-153.
18. +-channels and suppresses micturition reflex in rats. J. Urol. (1998) 159(Suppl. 5).
19. BRIONI JD, MORELAND RB: American Urological Association - 95th Annual Meeting. IDrug (2000) 3(7):762-765.
20. TANAKA M, SASAKI Y, KIMURA Y, FUKUI T, HAMADA K, UKAI Y: A novel pyrrole derivative, NS-8, suppresses the rat micturition reflex by inhibiting afferent pelvic nerve activity. BJU Int. (2003) 92(9):1031-1036.
21. LU SH, YAMAGATA T, ATSUKI K et al.: Effect of KW-7158, a putative afferent nerve inhibitor, on bladder and vesico-vascular reflexes in rats. Brain Res. (2002) 946(1):72-78.
22. CHAPPLE C, PATRONEVA A, RAINES RS: Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). Eur Urol. (2006) 49:879-886.
23. COCKAYNE DA, HAMILTON SG, ZHU QM et al.: Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-defident mice. Nature (2000) 407:1011-1015.
24. VLASKOVSKA M, KASAKOV I, RONG W et al.: G.P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J. Neurosci. (2001) 21:5670-5677.
25. KIBBLE A. Division of medicinal chemistry - P2 nucleotide receptors. IDrugs (2000) 3(11): 1270-1271.
26. EMONDS-ALX X, PROIETTO V, STEINBERG R et al.: SSR240600 [(R)-2-1-[2-[4-[2-[3,5-bis(trifluoromethyl)-phenyl] acethyl-2-(3,4-(dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)- 2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor. I. biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. (2002) 303 (3):1171-1179.
27. MICHEL MC: Lower urinary tract disorders - Ray Fuller Symposium, physiology, pharmacology and therapeutic approaches. IDrngs (2002) 5:792-796.
28. GREEN SA, ALON A, IANUS J, MCNAUGHTON KS, TOZZI CA, REISS TF: Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J. Urol. (2006) 176:2535-2540.
29. SUM FW, WONG V, HAN S, LARGIS E, MULVEY R, TILLETT J: Cyclic amine sulfonamides as linkers in the design and synthesis of novel human β(3) adrenergic receptor agonists. Bioorg. Med. Chem. Lett. (2003) 13(13):2191-2194.
30. 3 adrenoceptor agonism decreases motility and induces anti-hyperalgesia: a novel target for IBS. Gastroenterology (2006) 130(4 Suppl. 2).
31. 3 adrenergic receptor agonist, evokes bladder relaxation and increases mictrurition reflex threshold in the dog. Abstracts of the American Urological Association Annual Meeting, San Antonio, Texas, USA (21 - 26 May 2005). J. Urol. (2005) 173(Suppl. 4):1-467.
32. 3-adrenoceptor agonist, on bladder function in ran. Neurourol. Urodyn. (2002) 21(4):405-406.
33. ANDERSSON KE: Treatment of overactive bladder: other drug mechanisms. Urology (2000) 55:51-57.
34. CRESCIOLI C, MORELLI A, ADORINI L et al.: Human bladder as a novel target for vitamin D receptor ligands. J. Endocrinol. Metab. (2004) 90(2):962-972.
35. MORELLI A. VIGNOZZI L, FILIPPI S et al.: BXL-628, a vitamin D receptor antagonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate (2006) (In Press).
36. HUFF FJ: Preliminary evaluation of besipirdine for the treatment of Alzheimer's disease. Besipirdine study group. Ann. NY Acad Sci. (1996) 777:410-414.
37. BRUBAKER L, CHAPPLE C, COYNE KS, KOPP Z: Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Uroogy (2006) 68(Suppl. 2):3-8.
38. VOELKER R: International group seeks to dispel incontinence "taboo". JAMA (1998) 280:951.
39. CHAPPLE C: Interview with Chris Chapple. Overactive bladder: tackling the problem. Eur Urol. (2006) 49(5):921-923.
40. OUSLANDER JG: Management of overactive bladder. N. Engl. J. Med. (2004) 350(8):786-799.